The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
Pre-workout energy: I take the Nano Methyl B-12 before training, and its become my go-to pre-work supplement
10.1093/geronj/11.3.298 54 HerranzN.GilJ
Successful clinical translation will depend on identifying predictive biomarkers, optimizing the timing and sequence of combination therapies, and developing agents capable of selectively modulating these pathways within the tumor microenvironment
These effects work together to promote gradual, steady weight loss over time
We remove traditional barriers like long commutes, clinic waitlists, costly memberships, and unnecessary judgment
